Stock Scorecard
Stock Summary for Annovis Bio Inc (ANVS) - $1.98 as of 5/27/2025 3:53:54 PM EST
Total Score
12 out of 30
Safety Score
23 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ANVS
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ANVS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ANVS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ANVS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ANVS (23 out of 100)
| Stock Price Rating (Max of 10) | 2 |
| Historical Stock Price Rating (Max of 10) | 6 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ANVS
Financial Details for ANVS
Company Overview |
|
|---|---|
| Ticker | ANVS |
| Company Name | Annovis Bio Inc |
| Country | USA |
| Description | Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | 8/12/2025 |
Stock Price History |
|
| Last Day Price | 1.98 |
| Price 4 Years Ago | 17.58 |
| Last Day Price Updated | 5/27/2025 3:53:54 PM EST |
| Last Day Volume | 277,947 |
| Average Daily Volume | 443,114 |
| 52-Week High | 17.88 |
| 52-Week Low | 1.11 |
| Last Price to 52 Week Low | 78.38% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 21.34 |
| Sector PE | 39.72 |
| 5-Year Average PE | -4.52 |
| Free Cash Flow Ratio | 0.00 |
| Industry Free Cash Flow Ratio | 16.88 |
| Sector Free Cash Flow Ratio | 31.24 |
| Current Ratio Most Recent Quarter | 8.88 |
| Total Cash Per Share | 1,141.12 |
| Book Value Per Share Most Recent Quarter | 1.23 |
| Price to Book Ratio | 1.60 |
| Industry Price to Book Ratio | 34.13 |
| Sector Price to Book Ratio | 29.89 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 146.12 |
| Sector Price to Sales Ratio Twelve Trailing Months | 39.44 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 19,486,200 |
| Market Capitalization | 38,582,676 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -43,651.76% |
| Reported EPS 12 Trailing Months | -2.24 |
| Reported EPS Past Year | -0.32 |
| Reported EPS Prior Year | -2.44 |
| Net Income Twelve Trailing Months | -18,186,311,071 |
| Net Income Past Year | -24,590,375,000 |
| Net Income Prior Year | -56,204,313 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 22,236,175,000 |
| Total Cash Past Year | 10,551,916 |
| Total Cash Prior Year | 5,754,720 |
| Net Cash Position Most Recent Quarter | 22,236,175,000 |
| Net Cash Position Past Year | 10,551,916 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 499,807 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 9,307,646,000 |
| Total Stockholder Equity Prior Year | -7,750,846 |
| Total Stockholder Equity Most Recent Quarter | 24,053,887,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -8,114,025,852 |
| Free Cash Flow Per Share Twelve Trailing Months | -416.40 |
| Free Cash Flow Past Year | -21,894,604,000 |
| Free Cash Flow Prior Year | -39,967,304 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.13 |
| MACD Signal | 0.07 |
| 20-Day Bollinger Lower Band | -0.21 |
| 20-Day Bollinger Middle Band | 2.42 |
| 20-Day Bollinger Upper Band | 5.05 |
| Beta | 1.45 |
| RSI | 60.14 |
| 50-Day SMA | 5.79 |
| 150-Day SMA | 10.13 |
| 200-Day SMA | 13.29 |
System |
|
| Modified | 5/26/2025 5:25:06 PM EST |